论文部分内容阅读
同种异体骨髓移植(BMT)已从高度实验阶段发展到对各种疾病的临床应用阶段,而且在过去二十年间应用逐渐增加。70年代,BMT仅应用于恶性疾病的晚期,因而长期生存率低。80年代,恶性疾病早期进行BMT的病例日益增多,并且也成为一些非恶性血液病的选择性治疗。而且同种异体BMT一般应用于希望长期生存的年青患者(年龄小于40岁),因而长期生存率逐渐增加。这些变化提示,在90年代,BMT的晚期并发症可能是一个主要问题。关于BMT后恶性并发症的危险因素的资料几乎没有见到。本文作者将简述在BMT后所报道的三种恶性并发症,即白血病、淋巴
Allogeneic bone marrow transplantation (BMT) has evolved from a highly experimental stage to a clinical application stage for various diseases and has been gradually increasing in use over the past two decades. In the 1970s, BMT was only applied to the advanced stage of malignant disease, so the long-term survival rate is low. In the 1980s, there were increasing numbers of cases of early-stage BMT of malignant disease and also as a selective treatment for some non-hematologic malignancies. Moreover, allogeneic BMT is generally applied to young patients (less than 40 years of age) who wish to survive long-term, resulting in an increase in long-term survival. These changes suggest that late complications of BMT may be a major problem in the 1990s. Information on the risk factors for post-BMT malignant complications is rarely seen. The authors will outline the three malignant complications reported after BMT, namely leukemia, lymph